Co-targeting of the PI3K pathway improves the response of BRCA1 deficient breast cancer cells to PARP1 inhibition.
about
BRCA1 and estrogen/estrogen receptor in breast cancer: where they interact?Strategies for the Use of Poly(adenosine diphosphate ribose) Polymerase (PARP) Inhibitors in Cancer Therapy.Poly(ADP-ribose) contributes to an association between poly(ADP-ribose) polymerase-1 and xeroderma pigmentosum complementation group A in nucleotide excision repair.Profiling of alternative polyadenylation sites in luminal B breast cancer using the SAPAS method.Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.Triple-negative breast cancer: are we making headway at least?An Autoimmune Response Signature Associated with the Development of Triple-Negative Breast Cancer Reflects Disease Pathogenesis.PARG deficiency is neither synthetic lethal with BRCA1 nor PTEN deficiencyTriple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway.PIK3CA mutations are frequently observed in BRCAX but not BRCA2-associated male breast cancer.Systemic therapy options in BRCA mutation-associated breast cancer.Opportunities and hurdles in the treatment of BRCA1-related breast cancer.PI3K/AKT/mTOR pathway inhibitors: the ideal combination partners for breast cancer therapies?INPP4B overexpression enhances the antitumor efficacy of PARP inhibitor AG014699 in MDA-MB-231 triple-negative breast cancer cells.Combined drug therapeutic strategies for the effective treatment of Triple Negative Breast Cancer.How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies.
P2860
Q26822737-02F52129-D791-4741-B9E1-944EC85074B2Q33649555-2C7EAC2E-79C5-4918-9A42-EE8813E537BBQ34434424-9E1DCBF2-C514-46A2-9B10-4674D534E63DQ34599019-B6B8E8D4-E330-433F-92E3-B5D23C47B685Q35588352-D3F1FCC0-4CF6-4559-BBFD-06DC77AFB6ABQ36061177-B6AD3862-DD40-43DE-8E9F-6B980EBA2F3BQ36365669-BD1BBEF1-0BD1-400B-850A-12C3219AEFD9Q37057758-348B4228-1341-47E6-80AF-5EE7A1B8A9BAQ37645090-B0B1D3F1-8431-4BCA-8D14-2A09694ADFB8Q37690197-46BB922B-E29D-4969-8240-A5704AC7FCDFQ38025991-38298C87-1670-4B4D-B148-74D9E8B96A5AQ38129725-49515315-3962-42C3-B6AE-86C5DC041D96Q38259259-7FF82190-1216-41FC-8CA3-3AAD56CE7496Q39034710-284373B6-4B54-4878-97BB-95E2D03C9B0AQ48551091-EB4B1DC4-7FC5-48A0-AC91-1DD9F2E092F7Q54965602-57BA167F-533A-4483-9A7F-466C3992E86D
P2860
Co-targeting of the PI3K pathway improves the response of BRCA1 deficient breast cancer cells to PARP1 inhibition.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Co-targeting of the PI3K pathw ...... cer cells to PARP1 inhibition.
@en
Co-targeting of the PI3K pathw ...... cer cells to PARP1 inhibition.
@nl
type
label
Co-targeting of the PI3K pathw ...... cer cells to PARP1 inhibition.
@en
Co-targeting of the PI3K pathw ...... cer cells to PARP1 inhibition.
@nl
prefLabel
Co-targeting of the PI3K pathw ...... cer cells to PARP1 inhibition.
@en
Co-targeting of the PI3K pathw ...... cer cells to PARP1 inhibition.
@nl
P2093
P50
P1433
P1476
Co-targeting of the PI3K pathw ...... cer cells to PARP1 inhibition.
@en
P2093
Astrid Ottosson-Wadlund
Ewa Biskup
Heather Cunliffe
Ida Johansson
Kristina Aaltonen
Niklas Loman
Pontus Berglund
Siker Kimbung
Sofia Gruvberger-Saal
P304
P356
10.1016/J.CANLET.2012.01.015
P407
P577
2012-01-20T00:00:00Z